Enabling Projects
|
|||
Start Date |
Project Title |
Principle Investigator(s) |
Total Project Funding |
April 1, 2020 |
Kevin Hay, BC Cancer |
BioCanRx funding: $450,000 Partner contributions: § BC Cancer Foundation $ 300,000 § National Research Council of Canada $200,000 (in-kind) Total Funding: $950,000 |
|
Robert Holt, BC Cancer |
|||
Brad Nelson, BC Cancer |
|||
July 1, 2020 |
Development of a virally programmed exosome-based cancer vaccine platform |
Carolina Ilkow, The Ottawa Hospital Research Institute |
BioCanRx funding: $616,500 Partner contributions: § Canadian Cancer Society $ 150,000 § McMaster University $60,000 § The Ottawa Hospital Research Institute $120,000 § Ontario Institute for Cancer Research $140,000 (cash & in-kind) § FACIT $1,045,000 (cash & in-kind) § Terry Fox Research Institute $180,000 Total Funding: $2,311,500 |
Brian Lichty, McMaster University |
|||
John Bell, The Ottawa Hospital Research Institute |
|||
July 1, 2020 |
Michel Duval, CHU Sainte-Justine |
BioCanRx funding: $445,500 Partner contributions: § CHU Ste-Justine/Charles Bruneau Foundation $ 495,000 (cash & in-kind) Total Funding: $940,500 |
|
July 1, 2020 |
Jean-Simon Diallo, Ottawa Hospital Research Institute |
BioCanRx funding: $449,829 Partners: § TBA: $566,304 Total Funding: $1,016,133 |
|
Christopher Boddy, University of Ottawa |
|||
Jeffrey Smith, Carleton University |
|||
October 1, 2020 |
Scott McComb, National Research Council of Canada/ |
BioCanRx funding: $450,000 Partners: § BC Cancer Foundation $200,000 (in-kind) § TBA $300,000 Total Funding: $950,000 |
|
Natasha Kekre, Ottawa Hospital Research Institute |
|||
Robert Holt, BC Cancer |
|||
John Webb, BC Cancer |
|||
Kevin Hay, BC Cancer |
|||
October 1, 2020 |
Recombinant TCRs to target KRAS hotspot mutations in pancreatic cancer |
Robert Holt, BC Cancer |
BioCanRx funding: $450,000 Partner contributions: § BC Cancer Foundation $ 480,000
§ Chaire Roger Des Groseillers d’oncologie chirurgicale $20,000 Total Funding: $950,000 |
Simon Turcotte, Université de Montréal |
Clinical, Social, & Economic Impact (CSEI) Projects
|
||||
Start Date |
Project Title |
Principle Investigator(s) |
Total Project Funding |
|
March 26, 2019 |
Kednapa Thavorn, The Ottawa Hospital Research Institute |
BioCanRx funding: $100,000 Partner contributions: § Ontario Institute for Cancer Research $184,955 § ICES § Ottawa Methods Centre § The Ottawa Hospital Research Institute Total Funding: $284,955 |
||
Harry Atkins, The Ottawa Hospital Research Institute |
||||
Natasha Kekre, The Ottawa Hospital Research Institute |
||||
April 1, 2019 |
Kelvin Chan, Sunnybrook Research Institute |
BioCanRx funding: $100,000 Partner contributions: § Ontario Institute for Cancer Research $197,217 § Ontario Health (Cancer Care Ontario) $40,540 (in-kind) § Canadian Centre for Applied Research in Cancer Control $11,160 (in-kind) Total Funding: $348,917 |
||
Scott Gavura, Ontario Health |
||||
Wanrudee Isaranuwatchai, Unity Health |
||||
July 1, 2020 |
Identifying effect modifiers for CAR-T cell therapeutic efficacy |
Dean Fergusson, The Ottawa Hospital Research Institute |
BioCanRx funding: $100,058 Partner contributions: § Ottawa Methods Centre $50,000 (in-kind) § Cell Therapy Transplant Canada $10,000 (in-kind) § Leukemia & Lymphoma Society of Canada $10,000 (in-kind) § BLUEPRINT Translational Research Group $10,000 (in-kind) § National Research Council of Canada $10,000 (in-kind) Total Funding: $190,058 |
|
October 1, 2020 |
Manoj Lalu, The Ottawa Hospital Research Institute |
BioCanRx funding: $361,490 Partners: § TBA Total Funding: $361,490 |
||
Dean Fergusson, The Ottawa Hospital Research Institute |
||||
Justin Presseau, The Ottawa Hospital Research Institute |
*** The funding for these projects was announced on an earlier date.
Clinical Trial Projects
|
|||
Start Date |
Project Title |
Principle Investigator(s) |
Total Project Funding |
Rebecca Auer, The Ottawa Hospital |
BioCanRx funding: $750,000 Partner contributions: § Immodulon Therapeutics $400,000 (in-kind) § Canadian Centre for Applied Research in Cancer Control $50,000 § The Ottawa Hospital Foundation $25,000 § Ontario Institute for Cancer Research (OICR) $100,000 (in-kind) § The Ottawa Hospital Academic Medical Organization $96,000 § ATGen $44,500 (in-kind)
§ Canadian Cancer Trials Group (CCTG)/ Canadian Cancer $1,368,611 (cash + in-kind) Total Funding: $2,834,111 |
||
Christopher O’Callaghan, Queen’s University |
|||
April 1, 2020 |
Aly-Khan Lalani, McMaster University |
BioCanRx funding: $489,872 Partner contributions: § Bristol-Myers Squibb $774,349 § Ontario Clinical Oncology Group $77,435 (cash & in-kind) Total Funding: $1,341,656 |
|
Jonathan Bramson, McMaster University |
|||
Michael Surette, McMaster University |
|||
October 1, 2020 |
The Selected Tumor-infiltrating lymphocyte Against Refractory Melanoma-01 Trial (STAR-M01) |
Simon Turcotte, Centre hospitalier de l’Université de |
BioCanRx funding: $675,000 Total partner funding: $2,305,850 § Iovance Biotherapeutics § Institut du cancer de Montréal
§ Centre de Recherche du Centre Hospitalier de l’Université § Héma-Québec § Canada Research Chair in Patient and Public Partnership Total Funding: $2,980,850 |
October 1, 2020 |
Denis Claude Roy, Hôpital Maisonneuve-Rosemont |
BioCanRx funding: $675,000 Partner contributions: § HMR-CIUSSS-East-of-Montreal $800,000 § CellCAN $20,000 § C3i $100,000 (in-kind) Total Funding: $1,595,000 |
*** The funding for these projects was announced on an earlier date.
Core & Biomanufacturing Facilities
|
|||
CORE FACILITIES |
|||
Start Date |
Project Title |
Principle Investigator(s) |
Total Project Funding |
April 1, 2020 |
Molecular & Cellular Immunology Core (MCIC), BC Cancer |
Brad Nelson, BC Cancer |
BioCanRx funding: $300,000 |
July 1, 2020 |
Human Immune Testing Suite (McMaster University) |
Jonathan Bramson, McMaster University |
BioCanRx funding: $283,366 |
September 1, 2020 |
Alberta Cell Therapy Manufacturing Centre |
Gregory Korbutt, University of Alberta |
BioCanRx funding: $3,391,004 Partner contributions: § TBA: $4,499,380 Total Funding: $7,890,384 |
September 1, 2020 |
Conconi Family Immunotherapy Lab |
Brad Nelson, BC Cancer |
|
John Webb, BC Cancer |
|||
September 1, 2020 |
The Ottawa Hospital Biotherapeutics Manufacturing Centre |
John Bell, The Ottawa Hospital Research Institute |
|
October 31, 2020 |
Three New Point-of-Care Manufacturing Sites; locations TBA |
TBA |